Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome granted non-statutory stock options to purchase an aggregate of 344,000 shares to seventeen new employees under its 2024 Inducement Plan. The options have an exercise price of $21.49 per share, equal to the closing sales price on July 1, 2026, and will vest over four years.
Key figures
- Exercise price
- 21.49
- Shares granted
- 344000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.